Cancer immunotherapy: Overview of immune checkpoint inhibitors

Faisal Fa'ak; Adi Diab

doi:10.1007/978-3-030-56824-5_2

Cancer immunotherapy: Overview of immune checkpoint inhibitors

Faisal Fa'ak, Adi Diab

Section of Medical Oncology

Research output: Chapter in Book/Report/Conference proceeding › Chapter › peer-review

Abstract

Cancer treatment has been fully transformed with the development of cancer immunotherapies. The progress in the understanding of the immune system has led to the development of monoclonal antibodies targeted against regulatory immune checkpoints, which control T-cell activation. These therapies produce an antitumor response characterized by constant surveillance, specificity against tumor antigen, and long-lasting memory to protect against tumor relapse. In this chapter, we will discuss seven Food and Drug Administration-approved immune checkpoint inhibitors for the treatment of various malignancies, targeting two main signaling pathways, cytotoxic T-lymphocyte antigen 4 and programmed cell death 1/programmed cell death ligand-1.

Original language	English
Title of host publication	Rheumatic Diseases and Syndromes Induced by Cancer Immunotherapy
Subtitle of host publication	A Handbook for Diagnosis and Management
Publisher	Springer International Publishing
Pages	31-47
Number of pages	17
ISBN (Electronic)	9783030568245
ISBN (Print)	9783030568238
DOIs	https://doi.org/10.1007/978-3-030-56824-5_2
State	Published - Feb 16 2021

Keywords

Anti-CTLA4 inhibitors
Anti-PD-1 inhibitors
Anti-PD-L1 inhibitors
Cancer immunotherapy
Immune checkpoint inhibitors

Access to Document

10.1007/978-3-030-56824-5_2

Cite this

@inbook{d8473dcf3d464a30bbaf2aec2b4051f8,

title = "Cancer immunotherapy: Overview of immune checkpoint inhibitors",

abstract = "Cancer treatment has been fully transformed with the development of cancer immunotherapies. The progress in the understanding of the immune system has led to the development of monoclonal antibodies targeted against regulatory immune checkpoints, which control T-cell activation. These therapies produce an antitumor response characterized by constant surveillance, specificity against tumor antigen, and long-lasting memory to protect against tumor relapse. In this chapter, we will discuss seven Food and Drug Administration-approved immune checkpoint inhibitors for the treatment of various malignancies, targeting two main signaling pathways, cytotoxic T-lymphocyte antigen 4 and programmed cell death 1/programmed cell death ligand-1.",

keywords = "Anti-CTLA4 inhibitors, Anti-PD-1 inhibitors, Anti-PD-L1 inhibitors, Cancer immunotherapy, Immune checkpoint inhibitors",

author = "Faisal Fa'ak and Adi Diab",

year = "2021",

month = feb,

day = "16",

doi = "10.1007/978-3-030-56824-5_2",

language = "English",

isbn = "9783030568238",

pages = "31--47",

booktitle = "Rheumatic Diseases and Syndromes Induced by Cancer Immunotherapy",

publisher = "Springer International Publishing",

}

TY - CHAP

T1 - Cancer immunotherapy

T2 - Overview of immune checkpoint inhibitors

AU - Fa'ak, Faisal

AU - Diab, Adi

PY - 2021/2/16

Y1 - 2021/2/16

N2 - Cancer treatment has been fully transformed with the development of cancer immunotherapies. The progress in the understanding of the immune system has led to the development of monoclonal antibodies targeted against regulatory immune checkpoints, which control T-cell activation. These therapies produce an antitumor response characterized by constant surveillance, specificity against tumor antigen, and long-lasting memory to protect against tumor relapse. In this chapter, we will discuss seven Food and Drug Administration-approved immune checkpoint inhibitors for the treatment of various malignancies, targeting two main signaling pathways, cytotoxic T-lymphocyte antigen 4 and programmed cell death 1/programmed cell death ligand-1.

AB - Cancer treatment has been fully transformed with the development of cancer immunotherapies. The progress in the understanding of the immune system has led to the development of monoclonal antibodies targeted against regulatory immune checkpoints, which control T-cell activation. These therapies produce an antitumor response characterized by constant surveillance, specificity against tumor antigen, and long-lasting memory to protect against tumor relapse. In this chapter, we will discuss seven Food and Drug Administration-approved immune checkpoint inhibitors for the treatment of various malignancies, targeting two main signaling pathways, cytotoxic T-lymphocyte antigen 4 and programmed cell death 1/programmed cell death ligand-1.

KW - Anti-CTLA4 inhibitors

KW - Anti-PD-1 inhibitors

KW - Anti-PD-L1 inhibitors

KW - Cancer immunotherapy

KW - Immune checkpoint inhibitors

UR - http://www.scopus.com/inward/record.url?scp=85149187979&partnerID=8YFLogxK

U2 - 10.1007/978-3-030-56824-5_2

DO - 10.1007/978-3-030-56824-5_2

M3 - Chapter

AN - SCOPUS:85149187979

SN - 9783030568238

SP - 31

EP - 47

BT - Rheumatic Diseases and Syndromes Induced by Cancer Immunotherapy

PB - Springer International Publishing

ER -

Cancer immunotherapy: Overview of immune checkpoint inhibitors

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Cite this